Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study.

about

Aflibercept in Diabetic Macular Oedema Previously Refractory to Standard Intravitreal Therapy: An Irish Retrospective Study.

Item

http://www.wikidata.org/entity/Q53704361

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Aflibercept in Diabetic Macula ...... An Irish Retrospective Study.

@en

Aflibercept in Diabetic Macula ...... An Irish Retrospective Study.

@nl

type

Item

label

Aflibercept in Diabetic Macula ...... An Irish Retrospective Study.

@en

Aflibercept in Diabetic Macula ...... An Irish Retrospective Study.

@nl

prefLabel

Aflibercept in Diabetic Macula ...... An Irish Retrospective Study.

@en

Aflibercept in Diabetic Macula ...... An Irish Retrospective Study.

@nl

P1476

Aflibercept in Diabetic Macula ...... An Irish Retrospective Study.

@en

P2093

Ann-Marie Mongan

http://www.w3.org/2001/XMLSchema#string

Clare F McCloskey

http://www.w3.org/2001/XMLSchema#string

Darren M J McAteer

http://www.w3.org/2001/XMLSchema#string

Shauna M Quinn

http://www.w3.org/2001/XMLSchema#string

Shivona Chetty

http://www.w3.org/2001/XMLSchema#string

P2860

Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss

Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.

The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema.

Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration.

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.

Global prevalence and major risk factors of diabetic retinopathy.

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab.

Aflibercept for Diabetic Macular Edema in Eyes Previously Treated With Ranibizumab and/or Bevacizumab May Further Improve Macular Thickness.

P2888

s40123-018-0123-0

P304

173-183

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40123-018-0123-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29508370

http://www.w3.org/2001/XMLSchema#string

P932

5997601

http://www.w3.org/2001/XMLSchema#string